NCT06623955Completed
Maternal Serum Stathmin-1 Levels in Preeclampsia
A Comparative Study of Maternal Serum Stathmin-1 Levels in Pregnancies With Preeclampsia, Severe Preeclampsia, and Healthy Controls
Source: ClinicalTrials.gov · Last updated 2 Oct 2024
Brief summary (registry, in English)
This study investigates maternal serum Stathmin-1 (STMN-1) levels in pregnancies complicated by preeclampsia and severe preeclampsia, compared to healthy pregnancies. The aim is to explore potential differences in STMN-1 levels among these groups to better understand its role in preeclampsia pathophysiology. Maternal serum STMN-1 levels will be measured between 32-34 weeks of gestation, and patients will be monitored until delivery to assess whether they develop preeclampsia or severe preeclampsia.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 84 (actual)
- First submitted
- 24 Sept 2024
- Start date
- 1 Jan 2023
- Primary completion date
- 1 Jan 2024
- Lead sponsor
- Başakşehir Çam & Sakura City Hospital
- NCT number
- NCT06623955
What you commit to
- Study type: Observational
- Participants enrolled: 84
- From 1 Jan 2023 to the primary completion date, 1 Jan 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Pregestational Diabetes
- Chronic Hypertension
- Systemic Diseases (Chronic kidney disease, autoimmune diseases)
Other
- Multiple Pregnancies
- Fetal Anomalies
- Premature Rupture of Membranes
Who the study is looking for
- Clinical diagnosis of Preeclampsia: Defined by New-onset hypertension (Systolic Blood Pressure ≥140 mmHg and/or Diastolic Blood Pressure ≥90 mmHg) after 20 weeks of gestation, with or without proteinuria.
- Clinical diagnosis of Severe Preeclampsia: Defined by criteria such as severe hypertension (systolic BP ≥160 mmHg or diastolic BP ≥110 mmHg), organ dysfunction (renal insufficiency, liver involvement, neurological complications), thrombocytopenia, pulmonary edema, or fetal growth restriction.
- Control Group: Healthy pregnancies without preeclampsia
Age in the registry: 18 years to 40 years · Sex: Female · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Cam and Sakura City Hospital Coordinator of this site? Confirm its status | Istanbul | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.